ApoE Mounts A Comeback In Alzheimer’s
This article was originally published in Start Up
Executive Summary
New research has identified ApoE as a potential direct regulator of transcription, suggesting a broad role for the molecule in the study of Alzheimer’s disease that could explain why the usual strategies of trying to break up accumulations of amyloid beta or regulate tau hyperphosphorylation have failed to adequately treat symptoms or cure the disease.
You may also be interested in...
Targeting BRCA1 And DNA Repair In Alzheimer’s To Prevent Or Reverse Symptoms
New research has shown that levels of the DNA repair protein BRCA1 are reduced in key parts of neurons after amyloid formation. The findings are consistent with the amyloid hypothesis and could prove to be an effective way to help prevent or reverse the symptoms of Alzheimer’s disease and other neurodegenerative diseases.
Alzheimer’s R&D In Brief: Roche’s Crenezumab Misses Endpoints, Novartis Plans Large New Genetic Study
In data presented at the Alzheimer's Association International Conference in Copenhagen, held July 12-17, Roche’s anti-amyloid beta antibody misses endpoints in two Phase II studies, but there were some promising signs of efficacy.
Autophagy Mechanism In Schizophrenia Revealed
Most of the current industry interest in autophagy – a mechanism cells use to degrade and remove damaged material – is centered on its role as a cancer drug target, but autophagy is also a neuroprotective mechanism. Now, a research team has shown its involvement in schizophrenia, opening the door for new drug and diagnostic development efforts.